A5018028908- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Phagocytosis and Immune Regulation
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Polyomavirus and related diseases
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Brain Metastases and Treatment
USC Norris Comprehensive Cancer Center
2017-2025
University of Southern California
2017-2025
Ottawa Hospital
2024
Ottawa Hospital Research Institute
2024
Rutgers, The State University of New Jersey
2024
Rutgers New Jersey Medical School
2024
Keck Hospital of USC
2021-2023
Los Angeles Medical Center
2021
The University of Texas MD Anderson Cancer Center
2021
Hoag Memorial Hospital Presbyterian
2020
•This is a first-in-human dose-escalation/expansion study of PF-06939999, selective small-molecule inhibitor PRMT5.•Patients with selected solid tumors were treated PF-06939999 0.5-12 mg daily (q.d. or b.i.d.).•PF-06939999 had tolerable safety profile. Most common ≥G3 treatment-related AEs: hematological toxicities. RP2D: 6 q.d.•Response was seen in subset patients metastatic NSCLC and HNSCC, suggesting PRMT5 cancer therapeutic target.•No predictive biomarker identified. Additional mechanism...
Rationale: Monoacylglycerol lipase (Mgll), a hydrolase that breaks down the endocannabinoid 2-arachidonoyl glycerol (2-AG) to produce arachidonic acid (ARA), is potential target for neurodegenerative diseases, such as Alzheimer's disease (AD). Increasing evidence shows impairment of adult neurogenesis by perturbed lipid metabolism predisposes patients AD. However, it remains unknown what causes aberrant expression Mgll in AD and how Mgll-regulated impacts neurogenesis, thus predisposing...
2516 Background: AO-176 is a humanized IgG2 antibody that specifically targets CD47. Expressed by multiple tumor types, CD47 binds to signal regulatory protein (SIRPa) on phagocytes, including macrophages and dendritic cells. The CD47-SIRPa complex results in “don’t eat me” allows the escape removal innate immune system, disabling generation of an adaptive response. differentiated mechanisms action include promotion phagocytosis, direct cell killing through programmed death type III...
Brain metastases are a significant cause of mortality and morbidity for patients with melanoma. We hypothesize that the development brain may be explained by molecular heterogeneity between primary cutaneous melanoma (PCM) or extracranial (ECM) (MBM) metastases.We compared next-generation sequencing, tumor mutational burden (TMB), immunohistochemical staining PD-L1 expression, among 132 MBM, 745 PCM, 1190 ECM.The most common genetic alterations MBM included: BRAF (52.4%), NRAS (26.6%),...
TPS6107 Background: Ozuriftamab vedotin (BA3021) is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody (IgG1) conjugated to monomethyl auristatin E (MMAE) using cleavable linker (CAB ROR2 ADC) (Short, et al., 2014, Chang, al. 2021). Conditional and reversible binding by CABs designed reduce off-tumor toxicity immunogenicity, avoid tissue-mediated drug deposition, improve pharmacokinetics (PK). cell-surface transmembrane...
2522 Background: Immunotherapy combinations could be a promising strategy to overcome resistance existing therapies. AFM24, first in class, bispecific, tetravalent innate cell engager, binds CD16A on effector cells (NK and macrophages) EGFR solid tumors, redirecting enhancing the possibly adaptive immune response towards tumors. Atezolizumab, PD-L1 inhibitor, abrogates activation of PD-1 checkpoint, potentiating response. This Phase 1/2a study (NCT05109442) is evaluating if combining AFM24...
Race and ethnicity affect the distribution of molecular alterations seen in patients with non-small cell lung cancer (NSCLC). While anaplastic lymphoma kinase (ALK) are known to occur 4-5% population, data specific Hispanic population remains limited. This study describes real-world incidence ALK NSCLC treated at a large academic institution Los Angeles, California, USA further elucidate underlying factors that shape differences mutational profiles. 607 (NSCLC) Angeles General Medical Center...
Abstract Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages EGFR tumor cells, redirecting towards tumors. The safety tolerability of AFM24 was evaluated in this Phase 1/2a dose escalation/dose expansion study patients with recurrent or persistent, advanced tumors known to express EGFR. Methods: main objective 1 determine...
<p>Logistic regression for ALK alterations evaluating Hispanic ethnicity and controlling site of treatment, age at initial diagnosis, gender, smoking</p>
<p>Prevalence of adenocarcinoma histology, stage at diagnosis, and metastasis to brain by race/ethnicity</p>
<p>Initial ALK alteration identification by molecular testing</p>
<p>Reported ALK prevalence across the Hispanic populations in Latin America and Florida/Puerto Rico from literature search</p>
<p>Prevalence of ALK alterations, median age at diagnosis, prevalence males and females, never smokers, stage IV brain metastasis in the population by race/ethnicity</p>
<p>Summary of demographic features patients with NSCLC treated at the LAG and Norris</p>
<div>Abstract<p>Race and ethnicity affect the distribution of molecular alterations seen in patients with non–small cell lung cancer (NSCLC). Although anaplastic lymphoma kinase (ALK) are known to occur 4% 5% population, data specific Hispanic population remain limited. This study describes real-world incidence ALK NSCLC treated at a large academic institution Los Angeles, California, United States, further elucidate underlying factors that shape differences mutational profiles....
Abstract Background: Commercially available CTLA-4 antibodies are associated with a high incidence of immune mediated adverse events. Evalstotug (BA3071) is conditionally active biologic (CAB) anti–CTLA-4 monoclonal antibody that blocks the interaction its ligands in low-pH conditions tumor microenvironment. CABs not masked or caged and do require enzymatic cleavage for activation. They reversibly bound acidic microenvironment, which expected to reduce off-tumor immune-related events,...
<div>AbstractPurpose:<p>Innate immune cell–based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on NK cells/macrophages EGFR tumor cells, redirecting toward tumors. The safety tolerability of AFM24 were evaluated in this phase I/IIa dose-escalation/dose-expansion study patients with recurrent or persistent, advanced tumors known to express EGFR.</p>Patients...
<p>Supplementary Figure 3. Relationship between AFM24 concentrations and CD16A receptor occupancy on NK cells.</p>